Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/56736
Title: Ten-year outcome of different treatment modalities for squamous cell carcinoma of oral cavity
Authors: Imjai Chitapanarux
Patrinee Traisathit
Nicha Komolmalai
Sompol Chuachamsai
Pichit Sittitrai
Tienchai Pattarasakulchai
Rak Tananuwat
Donyarat Boonlert
Patumrat Sripan
Anak Iamaroon
Keywords: Biochemistry, Genetics and Molecular Biology
Medicine
Issue Date: 1-Jul-2017
Abstract: Objective: This study reports outcomes of squamous cell carcinoma of oral cavity (SCCOC) patients with different treatment modalities. Materials and Methods: We evaluated the treatment outcomes of 775 newly diagnosed SCCOC patients treated in our hospital between 2001 and 2010. Outcome data were obtained from the medical records. Survival rates were estimated by the Kaplan-Meyer method. Cox-proportional-hazard regression models were used to compare the risk of death among all risk factors. Results: The patients were divided into group 1) surgery ± adjuvant radiotherapy (RT) (n = 323) or group 2) RT ± chemotherapy (CT) for curative intent (n = 315) or group 3) RT/CT for palliative intent (n = 137). The overall 10-year survival rate was 17%. Statistically significant difference was noted in 10-year overall survival when SCCOC was managed surgically as compared to curative RT and palliative RT/CT with 25.3 %, 12.9%, 4.7%, respectively. The hazard ratio of cancer death in group 1 was 2.0 (95% CI 1.7-2.4) as compared to group 2. Conclusion: This study suggested that surgery must be the mainstay of treatment in locally advanced stage SCCOC. Palliative RT/CT still offered long term survival in some SCCOC patients.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85026247864&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56736
ISSN: 2476762X
15137368
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.